Cue biopharma announces initiation of investigator sponsored trial of cue-102 in recurrent glioblastoma multiforme

Boston, aug. 13, 2025 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells for the treatment of autoimmune disease and cancer, announced today the initiation of an investigator sponsored trial (ist) in rgbm at the dfci with the first patient in the trial having been dosed with cue-102. the trial (nct06917885) is a phase 1b, open-label study of adjuvant cue-102, the company's drug product candidate targeting wilms' tumor 1 protein (wt1) expressing cancers. the principal investigator of the phase 1b trial, david a. reardon, md, is the clinical director of the center for neuro-oncology at dfci and a leader in the field of immunotherapy for the treatment of brain cancer. the goal of the study is to evaluate the tolerability and clinical activity of cue-102 in patients with gbm at first recurrence.
CUE Ratings Summary
CUE Quant Ranking